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Major Depressive Disorder is a significant and costly cause of global disability. Until the 16 
discovery of the rapid acting antidepressant (RAAD) effects of ketamine, treatments were 17 
limited to drugs that have delayed clinical benefits. The mechanism of action of ketamine is 18 
currently unclear but one hypothesis is that it may involve neuropsychological effects 19 
mediated through modulation of affective biases (where cognitive processes such as 20 
learning and memory and decision-making are modified by emotional state). Previous work 21 
has shown that affective biases in a rodent decision-making task are differentially altered by 22 
ketamine, compared to conventional, delayed onset antidepressants.  This study sought to 23 
further investigate these effects by comparing ketamine with other NMDA antagonists using 24 
this decision-making task.  We also investigated the subtype selective GluN2B antagonist, 25 
CP-101,606 and muscarinic antagonist scopolamine which have both been shown to have 26 
RAAD effects.  Both CP-101,606 and scopolamine induced similar positive biases in 27 
decision-making to ketamine, but the same effects were not seen with other NMDA 28 
antagonists.  Using targeted medial prefrontal cortex (mPFC) infusions, these effects were 29 
localised to the mPFC.  In contrast, the GABAA agonist, muscimol, induced general 30 
disruptions to behaviour.  These data suggest that ketamine and other RAADs mediate a 31 
specific effect on affective bias which involves the mPFC.  Non-ketamine NMDA antagonists 32 
lacked efficacy and we also found that temporary inactivation of the mPFC did not fully 33 




Introduction   35 
Major Depressive Disorder (MDD) is a prevalent psychiatric disorder, affecting over 300 36 
million people globally1. It is the leading worldwide cause of disability, and, until recently, 37 
pharmacological treatments were limited to drugs that take weeks to improve symptoms and 38 
subjective reporting of mood2. The discovery of the rapid acting antidepressant (RAAD) 39 
effects of ketamine, an NMDA receptor antagonist, has rejuvenated the field by 40 
demonstrating that subjective changes in mood in depressed patients can be seen less than 41 
2 hours following administration and are sustained for at least 7 days in some patients3. 42 
Although this RAAD has been shown repeatedly4,5, 6,7,8, the mechanism underlying this effect 43 
is unclear, and better understanding could be critical for the development of new, fast-acting 44 
treatments.  45 
Patients with MDD exhibit affective biases, whereby impairments in emotional processing 46 
leads to reduced positive and/or enhanced negative biases in multiple cognitive domains, 47 
including attention, memory, emotional interpretation and decision-making9,10,11. In humans, 48 
acute (and chronic) treatment with conventional antidepressants induces positive biases in 49 
emotional memory and recognition in healthy controls12,13,14 and patients15, despite a lack of 50 
subjectively reported change in mood. It has been suggested that similar affective biases 51 
can also be measured in non-human animals using learning and memory tasks16 and in 52 
decision making under ambiguity (first demonstrated by Harding et al.17 using a judgement 53 
bias task). For review and more detailed discussion of translational studies of affective 54 
biases see Robinson and Roiser18. Judgement bias tasks (also known as cognitive bias 55 
tasks, or ambiguous cue interpretation tasks) were first developed as a cognitive test to 56 
measure animal affect (see reviews by Mendl et al.19 and Roelofs et al.20). In the task, 57 
animals are trained to associate the presentation two distinct reference cues with two 58 
differently valenced outcomes (e,g. positive: reward/high reward, or negative/less positive: 59 
punishment/low reward). After training, individuals are presented with untrained, ambiguous 60 




negative bias (more responses matching the positive or negative choice respectively). A 62 
recent systemic review and meta-analysis across judgement bias tasks in animals has 63 
shown that across 20 published research articles, pharmacological manipulations to induce 64 
changes in affective state overall did alter decision making about ambiguous cues as 65 
predicted21, demonstrating the validity of these types of tasks. In previous work in rodents in 66 
our lab using a reward-based judgement bias task (first reported by Hales et al.22), decision 67 
making biases were differentially altered by conventional, delayed acting antidepressants 68 
versus the RAAD ketamine24. In this task, where reference cues are associated with more or 69 
less positive outcomes22-24, we found that an acute, low dose of ketamine, but not acute 70 
treatment with another NMDA receptor antagonist, PCP, immediately induced more 71 
optimistic decision making, the direction that would be induced by a more positive affective 72 
state, whereas acute treatment with conventional antidepressants had no effect on bias24. 73 
However, when given chronically, the conventional antidepressant fluoxetine did induce a 74 
positive bias24, but only over a timescale similar to the drugs’ efficacy in patients, as 75 
measured by self-reported improvements in symptoms and mood25. The same pattern was 76 
also seen in this task with negative affective states, where a chronic stress manipulation, but 77 
not an acute stressor, induced more pessimistic decision making at later timepoints22.  78 
The aim of this study was to build upon these findings by testing a selection of other drugs 79 
that act via NMDA receptor antagonism: lanicemine, a low-trapping NMDA receptor channel 80 
blocker developed for the treatment of MDD, but failed to show efficacy in clinical trials26; 81 
memantine, an Alzheimer’s medication that is a moderate affinity, non-competitive NMDA 82 
receptor antagonist, but also lacked antidepressant efficacy in clinical trials5,27; and MK-801, 83 
a potent, non-competitive NMDA receptor antagonist that has shown RAAD efficacy in 84 
animal models28. We also tested other compounds that have been shown to have RAAD in 85 
human clinical trials: the GluN2B subunit selective NMDA receptor antagonist CP-101,60629, 86 
and the acetylcholine muscarinic receptor antagonist scopolamine30. We also tested 87 




range of receptor occupancy and in line with doses commonly used in preclinical animal 89 
models used to study depression31. To investigate the mechanism underlying the rapid 90 
positive change in decision-making bias we tested local administration of drugs shown to 91 
cause this effect directly into the prefrontal cortex (PFC), a brain area thought to be critical in 92 
the mechanism of RAAD of ketamine32,33 and previously shown to modulate learning biases 93 




Materials and Methods 95 
Animals and apparatus  96 
Three cohorts of male Lister Hooded rats (each cohort n=16) were used (Envigo, UK). Rats 97 
were pair-housed with environmental enrichment, consisting of a red 3 mm Perspex house 98 
(30x10x17cm), a large cardboard tube (10cm diameter), a wood chew block (9x2.5x2.5cm) 99 
and a rope tied across the cage lid (the rope was not present in cages for cohort 3 post-100 
surgery to avoid any possibility of implanted cannula getting caught). Animals were kept 101 
under temperature (19-23oC) and humidity (45-65%) controlled conditions on a 12-h reverse 102 
lighting cycle (lights off at 08:00h). Water was available ad libitum in the home cage, but rats 103 
were maintained at no less than 90% of their free-feeding body weight, matched to a 104 
standard growth curve, by restricting access to laboratory chow (LabDiet, PMI Nutrition 105 
International) to ~18g per rat per day. All procedures were carried out under local 106 
institutional guidelines (University of Bristol Animal Welfare and Ethical Review Board) and 107 
in accordance with the UK Animals (Scientific Procedures) Act 1986. Rats weighed 270-305 108 
g (cohort 1) / 250-295 g (cohort 2) / 240-290 g (cohort 3) at the start of training, and 400-465 109 
g (cohort 1) / 360-460 g (cohort 2) / 320-380 g (cohort 3) by the start of experimental 110 
manipulations. During experiments all efforts were made to minimise suffering including 111 
using a low stress method of drug administration35, and at the end of experiments rats were 112 
killed by giving an overdose of sodium pentobarbitone (200mg/kg). Behavioural testing was 113 
carried out between 0800 and 1800h, using standard rat operant chambers (Med 114 
Associates, Sandown Scientific, UK) as previously described22,24. Operant chambers 115 
(30.5x24.1x21.0cm) used for behavioural testing were housed inside a light-resistant and 116 
sound-attenuating box. They were equipped with two retractable response levers positioned 117 
on each side of the centrally located food magazine. The magazine had a house light (28V, 118 
100mA) located above it. An audio generator (ANL-926, Med Associates, Sandown 119 




above the left lever. Operant chambers and audio generators were controlled using K-Limbic 121 
software (Conclusive Solutions Ltd., UK).   122 
Judgement bias training 123 
Animals were trained and tested using a high versus low reward version of the judgement 124 
bias task as previously reported22,24. Rats were first trained to associate one tone (2kHz at 125 
83dB rats, designated high reward) with a high value reward (four 45mg reward pellets; 126 
TestDiet, Sandown Scientific, UK) and the other tone (8kHz at 66dB, designated low reward) 127 
with a low value reward (one 45mg reward pellet) if they pressed the associated lever (either 128 
left or right, counterbalanced across rats) during the 20s tone (see Figure 1 for a detailed 129 
depiction of the task). Unless otherwise specified in Table S1, response levers were 130 
extended at the beginning of every session and remained extended for the duration of the 131 
session (maximum one hour for all session types). All trials were self-initiated via a head 132 
entry into the magazine, followed by an intertrial interval (ITI), and then presentation of the 133 
tone. Pressing the incorrect lever during a tone was punished by a 10s timeout, as was an 134 
omission if the rat failed to press any lever during the 20s tone. Lever presses during the ITI 135 
were punished by a 10s timeout. During a timeout, the house light was illuminated, and 136 
responses made on levers were recorded but had no programmed consequences.  137 
Animals underwent a graduated training, and were required to meet criteria for at least two 138 
consecutive days before progressing to the next stage. Training stages were as follows:  139 
1) Magazine training: tone played for 20s followed by release of one pellet into 140 
magazine. Criteria:.20 pellets eaten for each tone frequency. 141 
2) Tone training: response on lever during tone rewarded with one pellet. Only one tone 142 
frequency, and one lever available per session. Criteria: >50 trials completed. 143 
3) Discrimination training: response on correct corresponding lever only during tone 144 
rewarded with one pellet. Both tones played (pseudorandomly) and both levers 145 




responses and no significant difference on any behavioural measures analysed over 147 
three sessions. 148 
4) Reward magnitude training: As for discrimination training but 2kHz tone now 149 
rewarded with four pellets, 8kHz tone rewarded with one pellet. Criteria: as for 150 
discrimination training but with >60% accuracy for both tones.  151 
All training sessions consisted of a maximum of 100 trials. Table S1 contains full details of 152 
training stages and criteria used. Rats were considered trained when they maintained stable 153 
responding for three consecutive days. This was after a maximum of 29 sessions for cohort 154 
1, 25 sessions for cohort 2, and 25 sessions for cohort 3 (see Table S1 for details of session 155 
numbers for each training stage). 156 
Judgement bias testing 157 
Baseline sessions (100 trials: 50 high and 50 low reward tones; presented pseudorandomly, 158 
for details see Table S1) were conducted on Monday and Thursday. Probe test sessions 159 
(120 trials: 40 high reward, 40 low reward, and 40 ambiguous midpoint tones that were 5kHz 160 
at 75dB; pseudorandomly, for details see Table S1) were conducted on Tuesday and Friday. 161 
The midpoint tone was randomly reinforced whereby 50% of trials had outcomes as for the 162 
high reward tone, and 50% had outcomes as for the low reward tone. This was to ensure a 163 
specific outcome could not be learnt, and to maintain responding throughout the experiments 164 
(see Figure 1 and Table S1 for a detailed description of how this was implemented). Cohort 165 
1 were used to test the effect of acute systemic treatments with putative RAAD and other 166 
NMDA receptor antagonists. Cohort 2 were made up of two groups of eight rats that had 167 
previously been used as control animals in another experiment (data not shown) and were 168 
then used for the extension of doses of ketamine and PCP. Cohort 3 were used for mPFC 169 
infusion experiments. For further details of the different treatments received by each cohort 170 




Study 1: the effect of acute, systemic treatments with RAADs and NMDA receptors 172 
antagonists on judgement bias. 173 
Experimental design: Each study used a within-subject fully counterbalanced drug 174 
treatment schedule (see Table S2 for details of individual treatments). The study design 175 
followed the same procedures as used in our earlier work characterising the effects of 176 
ketamine in the JBT24. We also included a replication study with systemic ketamine in our 177 
infusion cohort in order to confirm similar systemic effects before proceeding to the infusion 178 
studies. Each animal received all doses for any given treatment in a counter-balanced 179 
design with drug doses separated by a minimum of 72 hrs and at least a one-week drug free 180 
period between different treatments. There is the potential for compensatory changes to 181 
develop due to repeated testing and the drug treatments, but these are minimised by 182 
managing washout periods and also recording and analysing the animals’ baseline data in 183 
between drug studies. We are aware of the increasing evidence that ketamine, and 184 
potentially the other treatments tested, can have long lasting effects36 which may not fully 185 
reverse over this dosing schedule. The counterbalanced design does mitigate the risks of 186 
any bias of these schedules on the results but there may be carryover effects which could 187 
influence the main findings. We carry out analysis of the between treatment baseline 188 
sessions (data shown in Table S3-S6) and these analyses do not suggest that the 189 
behavioural parameters we measure were affected for any of the cohorts over time. All drugs 190 
were given by intraperitoneal injection using a low-stress, non-restrained technique35. 191 
Ketamine¥ (Sigma-Aldrich, UK), scopolamine§ (Tocris, UK), lanicemine¥ (Sigma Aldrich, UK), 192 
memantine¥ (Tocris, UK), MK-801§ (Tocris, UK) and PCP¥ (Sigma Aldrich, UK) were 193 
dissolved in 0.9% sterile saline and given 30§ or 60¥ minutes prior to testing. CP-101,606 194 
(Experiment 1: Sigma Aldrich, UK; Experiment 2: Boehringer Ingelheim GmbH) was 195 
dissolved in 5% DMSO, 10% cremaphor and 85% sterile saline and given 60 minutes prior 196 
to testing. Drug doses were selected based on previous rodent behavioural studies24,37. 197 




e.g. higher doses of ketamine and lower doses of PCP were used than previously24. For all 199 
studies, the experimenter was blind to drug dose. The order of testing for each cohort is 200 
displayed in Table S2.  201 
Study 2: mPFC cannulation and infusions 202 
mPFC cannulation: To localize the site and mechanism of action of RAAD drugs, rats were 203 
implanted with mPFC guide cannula. Rats were anesthetised with isoflurane/O2 and 204 
secured in a stereotaxic frame. Bilateral 32-gauge guide cannulae (Plastics One, UK) were 205 
implanted in the mPFC according to the stereotaxic coordinates: anteroposterior +2.7mm, 206 
lateral ±0.75mm and dorsoventral −2.0mm from bregma38. The cannulae were secured to 207 
the skull with gentamicin bone cement (DePuy CMW, UK) and stainless steel screws 208 
(Plastics One, UK). Animals received long acting local anaesthetic during surgery, and after 209 
surgery the animals were housed individually for 2-3 hours then allowed 10-13 days 210 
recovery in normal paired housing conditions. Following the recovery period, rats underwent 211 
one week of baseline sessions to re-establish performance. Following this, one week of 212 
probe testing was carried out to check that judgement of the ambiguous tone had not altered 213 
after surgery. Based on this, another two weeks of probe testing (4 test sessions) was then 214 
conducted.  215 
Systemic ketamine: Following this, an acute systemic treatment with ketamine was given 216 
as a positive control manipulation to ensure that bias could still be manipulated post-surgery. 217 
This study was a within-subject fully counterbalanced design, with two treatments (see Table 218 
S2, top row of section 3), with the experimenter blind to drug dose. Ketamine (1.0 mg/kg, 219 
Sigma Aldrich, UK) was dissolved in 0.9% sterile saline vehicle (0.0 mg/kg) and was given 220 
by intraperitoneal injection using a low-stress, non-restrained technique35 60 minutes prior to 221 
testing.  222 
Infusion Procedure: Rats were then used for mPFC infusion experiments. For details of the 223 




where animals were lightly restrained and the cannula dummy removed and then replaced. 225 
In a second habituation session animals were gently restrained while the cannula dummy 226 
was removed and a 33-gauge bilateral injector extending 2.5mm beyond the length of the 227 
guide cannula was inserted into the mPFC. This was left in place for two minutes, but no 228 
infusion occurred.  During experimental infusions, the rats were gently restrained while the 229 
cannula dummy was removed and the injector inserted. The injector was left in place for 230 
1 min prior to infusions of vehicle or drug (1.0μl total volume) over 2 minutes. The injector 231 
was left in place for a further 2 minutes to allow diffusion of the drug into the tissue 232 
surrounding the injector, and then the injector was removed and the dummy replaced. The 233 
ambiguous probe test session occurred 5 minutes after the dummy was replaced. 234 
Infusion experiments: In the first infusion experiment vehicle (sterile phosphate-buffered 235 
saline (PBS); 0.0μg/μl), ketamine (1.0μg/μl), muscimol (0.1μg/μl) or scopolamine (0.1μg/μl), 236 
all dissolved in sterile PBS, were infused intracerebrally into mPFC 5 minutes before testing. 237 
Following this, CP-101,606 (1.0μg/μl in the first study, 3.0μg/μl in the second study) was 238 
dissolved in 10% 2-hydroxypropyl-cyclodextrin and 90% PBS and tested. All experiments 239 
used a within-subject fully counterbalanced design for drug treatments, with the 240 
experimenter blind to treatment. Drug doses were chosen based on the results from acute, 241 
systemic treatments (see Table S2). 242 
Histology: Following the completion of mPFC infusions, rats were killed and brains were 243 
fixed and processed for histology. Rats were anesthetised with a lethal dose of sodium 244 
pentobarbitone (0.5ml Euthatal, 200mg/ml, Genus Express, UK) and perfused via the left 245 
ventricle with 0.01M PBS followed by 4% paraformaldehyde (PFA). The brains were 246 
removed and post-fixed in 4% PFA for 24 hours. Prior to being cut, brains were transferred 247 
to 30% sucrose in 0.1M PBS and left for 2 days until brains were no longer floating. Coronal 248 
sections were cut at 40μm on a freezing microtome and stained with Cresyl Violet. Locations 249 
of the injector tip positions in the mPFC were mapped onto standardised coronal sections of 250 




Data and statistical analysis 252 
Sample size was estimated based on our previous studies using the JBT22,24 but with a more 253 
conservative effect size as we were looking at acute rather than chronic effects and 254 
expected to see greater variation in mPFC infusion studies. Changes in judgement bias 255 
should occur without effects on other variables and therefore strict inclusion criteria were 256 
established to reduce any potential confound in the data analysis. Only animals which 257 
maintained more than 60% accuracy for each reference tone, and less than 50% omissions 258 
were used for analysis.  259 
Cognitive bias index (CBI) was used as a measure of judgement bias in response to the 260 
midpoint tone. CBI was calculated by subtracting the proportion of responses made on the 261 
low reward lever from the proportion of responses made on the high reward lever. This 262 
created a score between -1 and 1, where negative values represent a negative bias and 263 
positive values a positive bias. Change from baseline in CBI was then calculated for all 264 
experimental manipulations as follows: vehicle (0.0mg/kg) probe test CBI − drug dose probe 265 
test CBI. This was calculated to take into account individual differences in baseline bias, and 266 
to make directional changes caused by drug treatments clearer. To provide a value for 267 
vehicle probe test sessions for this measure, the population average for the vehicle 268 
(0.0mg/kg) probe test was taken away from each individual rats’ CBI score for this dose. 269 
This allowed this measure to be analysed with repeated measures analysis of variance 270 
(rmANOVA) with drug dose as the within-subjects factor for drug studies with more than two 271 
treatments, or paired samples t-test for studies with only two treatments. The raw data for 272 
CBI is included for all drug treatments in Figure S1-S2.  273 
Response latency and accuracy, omissions and premature responses were also analysed 274 
(see Table S8 for details of these). These measures were analysed with rmANOVAs with 275 
drug dose and tone as the within-subjects factors. Paired t-tests were performed as post-hoc 276 
tests if significant effects were established. Huynh-Feldt corrections were used to adjust for 277 




comparisons. All statistical tests were conducted using SPSS 24.0.0.2 for Windows (IBM 279 
SPSS Statistics) with α=0.05. Results are reported with the ANOVA F-value (degrees of 280 
freedom, error) and p-value as well as any post-hoc p-values. All graphs were made using 281 





Study 1: The effect of acute, systemic treatment with RAADs and selected NMDA receptor 284 
antagonists 285 
CP-101,606: One animal was excluded in experiments 1 and 2 as accuracy criteria was not 286 
met on the vehicle drug dose. In the initial dose response study, CP-101,606 treated animals 287 
did not overall show any change in CBI (no main effect of drug dose (F2.237,31.323=0.811, 288 
p=0.495). Due to the possibility that there might be small change in CBI for the highest dose 289 
(3.0mg/kg; visual inspection of the data and one sample t-test (not corrected for multiple 290 
comparisons): p=0.038; Figure 2A), we then tested a higher dose of CP-101,606 (6.0mg/kg) 291 
in the second experiment. This dose (6.0mg/kg) resulted in a positive bias relative to vehicle 292 
treatment (paired samples t-test: p=0.027; Figure 2A). In experiment 1, 3.0mg/kg CP-293 
101,606 also caused a decrease in response latency (main effect of drug dose: F3,42=4.858, 294 
p=0.005, post-hoc: p=0.027; Table S7). There were no effects on other behavioural 295 
measures in experiment 1 (Table S7). In experiment 2, CP-101,606 (6.0mg/kg) caused 296 
response latencies to decrease (main effect of drug dose: F1,14=27.396, p<0.001; Table S7). 297 
This dose had no effect on accuracy for the reference tones (Table S7), but did increase 298 
premature responses (paired samples t-test: p=0.001), and reduced omissions (main effect 299 
of drug dose: F1,14=10.506, p=0.006; Table S7). 300 
Scopolamine: The highest dose tested (0.3mg/kg) had to be excluded from the analysis as 301 
most rats did not complete sufficient trials. Scopolamine (0.1mg/kg) induced a positive bias 302 
(main effect of drug dose: F2,30=6.739, p=0.004, post-hoc: p=0.035; Figure 2B). This dose of 303 
scopolamine (0.1mg/kg) also increased response latencies (main effect of drug dose: 304 
F2,30=17.263, p<0.001, post-hoc: p=0.001; Table S7), increased premature responding (main 305 
effect of drug dose: F1.355,20.330=4.387, p=0.039, post-hoc: p=0.047; Table S7), and increased 306 
omissions for all tones (significant drug dose*tone interaction: F2.343,35.150=4.739, p=0.011, 307 
main effect of drug dose: F2,30=24.257, p<0.001, post-hoc: ps<0.001; Table S7). The lower 308 




increase (main effect of drug dose: F1.605,24.069=8.558, p=0.003, post-hoc: p=0.002; Table 310 
S7), and omissions to increase for all tones (post-hoc: ps≤0.019; Table S7).  311 
Ketamine: In the rats who had undergone mPFC cannulation surgery, ketamine (1.0mg/kg) 312 
caused a positive change in CBI (paired samples t-test: p=0.033; Figure 2C), as has been 313 
seen previously24. Ketamine did not alter any other behavioural measures (Table S7).  314 
Lanicemine: None of the doses of lanicemine tested caused a change in CBI (Figure 2D). 315 
This drug also had no effect on any other behavioural measures (Table S7). 316 
Memantine: Memantine did not cause any change in CBI at the doses tested (Figure 2E). 317 
There was also no effect on other behavioural measures (Table S7). 318 
MK-801: MK-801 did not change CBI (Figure 2F). The highest dose of MK-801 tested 319 
(0.03mg/kg) decreased response latencies (main effect of drug dose: F2,30=3.843, p=0.033; 320 
Table S7). There was no effect on accuracy for the reference tones, percentage omissions 321 
or premature responding.  322 
High-dose ketamine: In experiment 2 (25mg/kg ketamine) one rat was excluded for failure 323 
to complete sufficient trials. In experiments 1 and 2, ketamine (10mg/kg and 25mg/kg 324 
respectively) did not change CBI (Figure 3A). In both experiments these higher doses did 325 
alter all other behavioural measures. There was an increase in response latency across all 326 
three tones for both 10mg/kg (drug dose*tone interaction: F2,30=7.323, p=0.003, post-hoc: 327 
ps<0.001 for all tones; Figure 3C), and 25mg/kg ketamine (drug dose*tone interaction: 328 
F2,28=4.686, p=0.018, post-hoc: ps≤0.002 for all tones; Figure 3C). Both doses decreased 329 
premature responses (paired samples t-tests: 10mg/kg – p=0.005, 25mg/kg – p=0.006; 330 
Figure 3E). Ketamine also improved accuracy in experiment 1 (10mg/kg: main effect of drug 331 
dose: F1,15=8.774, p=0.010; Figure 3B) and for the low reward tone in experiment 2 332 
(25mg/kg: drug dose*tone interaction: F1,14 = 5.513, p=0.034, post-hoc: p=0.033; Figure 333 
3B). In both experiments, there was an increase in omissions for all three tones (experiment 334 




tone – p=0.015, midpoint tone: p=0.003, low reward tone: p=0.010; experiment 2, 25mg/kg: 336 
drug dose*tone interaction: F1.368,19.150=11.964, p=0.001, post-hoc: high reward tone – 337 
p=0.003, midpoint tone – p<0.001, low reward tone – p=0.001; Figure 3D).  338 
Low dose PCP: Doses of PCP (0.03, 0.1, 0.3mg/kg) that were lower than those previously 339 
tested24 did not cause any change in CBI (Figure 2G). There was also no effect on any other 340 
behavioural measures (Table S7). 341 
Analysis of performance split over session: In addition to the analyses above we also 342 
compared performance for the first and last 20 probe trials in order to check whether 343 
animals’ performance changed within a session during these randomly reinforced trials. 344 
Analysis of the data for doses of ketamine (1.0mg/kg), CP101606 (6.0mg/kg) and 345 
scopolamine (0.1mg/kg) which change CBI did not find any evidence of differences across 346 
the session between vehicle or drug treatments based on this analysis (see Figure S3).  347 
 348 
Study 2: mPFC infusions of drugs shown to cause positive judgement biases 349 
Two rats were excluded in cohort 3: one rat did not meet accuracy criteria for any probe (or 350 
baseline) session following the second drug infusion; and after the end of testing another 351 
animal was found to have an incorrect cannula placement. Therefore, both were excluded 352 
retrospectively from the entire study. Compared to pre-surgery performance, the CBI of rats 353 
became more negative after surgery, and this was stable across testing over three weeks 354 
(main effect of week: F3,42=6.335, p=0.001, post-hoc: ps≤0.011; Figure 4A). There were no 355 
differences in response latencies, premature responses, accuracies for reference tones or 356 
omissions before compared to after surgery (Table S7). The change in CBI occurred before 357 
infusions and seemed to be a response to the surgical intervention potentially causing a 358 
more negative affective state. We found no evidence of tissue damage in the area 359 
surrounding the cannula post-mortem, so it is unlikely that this was a result of trauma. We 360 




could cause a permanent negative change in affect. It is exactly this sort of affective state 362 
change that judgement bias assays have been developed to detect (for example see 363 
Bethell39, and Baciadonna & McElligott40 for reviews summarising how judgement bias tasks 364 
can be used as measure of animal welfare). 365 
In the first infusion experiment, ketamine (1.0μg/μl), muscimol (0.1μg/μl) and scopolamine 366 
(0.1μg/μl) all induced positive biases (main effect of drug dose: F3,36=7.241, p=0.001; post-367 
hoc: ketamine – p=0.012, muscimol – p=0.001, scopolamine – p=0.032 Figure 4C). The 368 
effect of PFC infusion of ketamine or scopolamine was specific to CBI, as these drugs had 369 
no effect on other behavioural measures (Figure 4D-G), unlike muscimol infusions which 370 
caused changes to all other behavioural measures. There was an increase in response 371 
latency (drug dose*tone interaction: F6,72=4.181, p=0.001) for the high reward (post-hoc: 372 
p<0.001) and midpoint tone (p=0.028; Figure 4E), and a large increase in premature 373 
responses to over 100% (main effect of drug dose: F1.151,13.809=33.784, p<0.001, post-hoc: 374 
p<0.001; Figure 4G). Muscimol also caused accuracy to decrease (main effect of drug dose: 375 
F1.181,14.172=43.775, p<0.001, post-hoc: p≤0.001; Figure 4D). For the low reward tone, this 376 
reduction was so great that rats were no longer performing any better than chance (one-377 
sample t-test against a test value of 50%: p=0.197; Figure 4D). Omissions increased 378 
following muscimol infusion (main effect of drug dose: F1.338,16.057=10.418, p=0.003, post-hoc: 379 
p=0.007; Figure 4F).  380 
In the experiments testing the effect of CP-101,606 mPFC infusion, in experiment 1 the 381 
lower dose (1.0μg/μl) did not alter CBI (Figure 5A), but in experiment 2, the higher dose 382 
(3.0μg/μl) induced a positive bias (paired samples t-test: p=0.043; Figure 5A). In experiment 383 
1, CP-101,606 (1.0μg/μl) caused an increase in response latency (main effect of drug dose: 384 
F1,12=5.064, p=0.044; Figure 5C) but had no other behavioural effects (Figure 5B,D,E). In 385 
experiment 2, 3.0μg/μl CP-101,606 did not have any effects on other behavioural measures 386 




Discussion  388 
As previously shown24, low dose ketamine (1.0mg/kg) had a specific effect on decision-389 
making biases, inducing a positive change in CBI following acute administration. This effect 390 
of ketamine was dose dependent, with higher doses having general effects on task 391 
performance without changing CBI. The effects of ketamine were recapitulated to some 392 
extent by the GluN2B antagonist, CP-101,606 and muscarinic antagonist, scopolamine, but 393 
both also had more general effects on other behavioural measures following systemic 394 
administration. All three treatments have previously been reported to have RADD effects in 395 
clinical trials3,29,30, whilst the other NMDA antagonists tested here did not5,26-28, and these 396 
also failed to induce a change in bias. The mPFC infusions suggest that this brain region is 397 
central to the effects of ketamine, scopolamine and CP-101,606. Interestingly, mPFC 398 
infusions more specifically altered bias, suggesting other brain regions may contribute to the 399 
systemic effects on other behavioural measures. The importance of the mPFC in modulating 400 
RAAD effects in neuropsychological tasks is consistent with previous findings in our learning 401 
and memory bias assay, the affective bias test34. Inactivation of the mPFC with muscimol did 402 
positively change bias but animals also exhibited large changes in other behavioural 403 
measures. This suggests that the RAADs can modulate activity in this brain region in a more 404 
specific way than muscimol, which results in a relatively specific effect on biases in decision-405 
making.   406 
For lanicemine and memantine, the lack of any behavioural effects means there is a 407 
possibility that the doses tested were too low. For both treatments the range of doses tested 408 
covers the doses that are equivalent to those used humans in clinical trials (lanicemine: 50, 409 
100mg26, equivalent to approximately 0.75, 1.5mg/kg; memantine: 5-20mg5, equivalent to 410 
approximately 0.07-0.3mg/kg), paralleling our effective dose of ketamine (1.0mg/kg, similar 411 
to the 0.5mg/kg dose used by Zarate et al.3). Although higher doses may yield behavioural 412 
effects, these are likely to be due to much higher levels of receptor occupancy than those 413 




receptors. When testing lower doses of PCP (another NMDA receptor antagonist not known 415 
to show RAAD) than previously used24, we also failed to see any change in CBI. Conversely, 416 
when we tested higher doses of ketamine than those we had previously24, doses that are 417 
often used to demonstrate antidepressant effects in other preclinical models used to study 418 
depression such as the forced swim test (FST)41, we failed to see any change in bias, 419 
instead only seeing non-specific changes in other behavioural measures. The behavioural 420 
profile seen with these higher doses of ketamine (increased response latency and omissions 421 
and decreased premature responding) suggests that these doses may be causing locomotor 422 
depression or reducing motivation to respond. Higher doses of ketamine have not been 423 
found to have antidepressant effects in clinical trials and these data also suggest that rodent 424 
studies using these higher doses may not be looking at specific effects. It may be that the 425 
lower 1.0mg/kg dose of ketamine can specifically alter decision making biases because they 426 
target a specific population and hence modulate a specific circuit. Some studies have 427 
suggested that ketamine may act via disinhibition of GABAergic interneurons leading to a 428 
glutamate burst which then activates prefrontal glutamate neurons42. Overall, the results 429 
from systemic administration of different NMDA receptor antagonists lends support to our 430 
interpretation that this reward-based judgement bias task can specifically dissociate between 431 
drugs that do show RAAD, and those that do not, despite them having similar pharmacology.  432 
The difference in specificity on behavioural effects, whereby ketamine (1.0mg/kg) only 433 
positively changes decision-making bias, but both CP-101,606 and scopolamine have other 434 
non-specific effects, suggests that 1.0mg/kg ketamine is able to relatively selectively 435 
modulate affective bias. The changes in response latencies, omissions and premature 436 
responses caused by CP-101,606 and scopolamine suggest that these drugs may also be 437 
having effects on other cognitive processes, such as motivation. However, the direction of 438 
changes for these drugs are in opposite directions (decreases in response latency and 439 
omissions for CP-101,606 but increases in these for scopolamine) despite them both 440 




reference tones, suggest that these non-specific effects cannot fully explain the change in 442 
decision-making bias. 443 
The neurobiology underlying the relative specificity of ketamine, CP-101,606 and 444 
scopolamine in being able to immediately alter decision-making bias, in contrast to the other 445 
NMDA receptor antagonists tested that have not shown these effects, are likely to be due to 446 
differences in their mechanisms of action. Our findings add weight to the strong body of 447 
evidence suggesting that NMDA receptor antagonism is important for short-term, RAAD 448 
effects of these drugs43, but suggests that specific modulation of either a specific subtype of 449 
the receptor or a sub-population of neurons may be involved. CP-101,606 is selective for the 450 
GluN2B NMDA receptor subunit, whilst it has been shown that scopolamine, and more 451 
recently ketamine, cause a glutamate burst via blockade of NMDA receptors specifically on 452 
GABA interneurons that leads to increased mechanistic target of rapamycin complex 1 453 
signalling, brain-derived neurotrophic factor release and synaptic changes in the PFC42,44-46. 454 
Further studies would be required to test whether these mechanisms also drive these drugs 455 
effects on affective bias. 456 
The infusion studies localise the site of action of this rapid change in decision-making bias to 457 
the mPFC, corresponding with brain imaging studies in humans that have also shown 458 
ketamine-dependent changes in prefrontal glutamatergic neurotransmission32,33. This also 459 
matches with previous rodent studies, where using the affective bias test, it has been shown 460 
that whilst ketamine does not induce positive biases in learning, it can remediate previously 461 
acquired negative biases, an effect which also localises to the mPFC34. For CP-101,606 and 462 
scopolamine, unlike when given systemically, intracerebral mPFC infusion did not cause any 463 
non-specific behavioural changes on the task. This could suggest that these non-specific 464 
effects are driven by off-target effects of drug binding in other brain areas, or in the case of 465 
scopolamine, the periphery. The localisation of the positive modulation of decision making 466 
caused by these drugs to the mPFC provides further support for the hypothesis that this 467 




been shown to cause the activation of downstream pathways thought to be important in the 469 
RAAD effects of both ketamine and scopolamine42,44-46. 470 
Interestingly, both GABAA receptor agonism (musciol infusion), and NMDA receptor 471 
antagonism (ketamine infusion) in the mPFC caused the same qualitative, but not 472 
quantitative behavioural change in judgement bias (a positive shift but of different 473 
magnitudes), mirroring findings seen previously with intra-infralimbic infusions of muscimol 474 
and (R)-CPP on the five choice serial reaction time task, where both drugs increased 475 
impulsive responding but by different amounts47. It has been suggested that the functional 476 
effects of NMDA receptor antagonism may be due to excess extracellular glutamate48,49. 477 
However, the pronounced, non-specific behavioural effects on other measures seen 478 
following muscimol infusion suggests that mechanism of action of the other infusion drugs is 479 
more refined than global inhibition of neurotransmission in the mPFC. Previous work in 480 
humans and rodents has shown that subcortical and limbic brain regions, such as the 481 
amygdala, are important in the neurocircuitry of MDD / depression-related behaviour50-52, 482 
and a recent study suggests that ketamine may play a critical role in restoring dysfunctional 483 
connectivity in these circuits33. Furthermore, in rodents, a recent study found that 484 
optogenetic activation of pyramidal mPFC neurons containing dopamine receptor D1 caused 485 
RAAD-like responses in the forced swim test, and that blockade of these receptors 486 
prevented the RADD effects of ketamine53. In order to further our understanding of this 487 
mechanism, it will be important to investigate the effects of these drugs on different neuronal 488 
subtypes within the mPFC, as well as investigating the wider circuitry that is altered by these 489 
drugs. 490 
 491 
Final conclusions 492 
This study adds to the evidence that the neuropsychological effects of ketamine are 493 




affective biases, both in decision-making as demonstrated here, as well as in learning and 495 
memory occur at time points (one hour) before major plastic changes arise. It will be 496 
important to investigate the neurobiological effects of not just the immediate, RAAD of 497 
ketamine, but also the sustained effects by examining how affective biases are altered at 498 
longer time points. Furthermore, investigation of the wider circuits involved in this RAAD 499 
efficacy will be crucial in revealing the mechanism underlying these actions, which will be 500 
important for the development of novel therapeutics. Ketamine (at 1.0mg/kg) seems to have 501 
very specific effects on affective bias, which we can capitalise on to better understand the 502 
circuits that contribute to these modulations of affective biases that are potentially very 503 
important in the cause, perpetuation and treatment of MDD. More detailed circuit analyses 504 
are needed including undertaking studies in other brain regions to determine whether 505 
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Figure Legends 677 
Figure 1 – Schematic of the judgement bias task and trial structure. 678 
In the judgement bias task (JBT), rats are trained to associate one tone frequency (2kHz) 679 
with a high value reward: i.e. if the rat presses the correct lever (shown as the left lever in 680 
(A), but counterbalanced across rats in a cohort) they receive a high value reward (four 681 
reward pellets). They also learn to associate a second tone frequency (8kHz) with receiving 682 
a low value reward (one reward pellet; shown in (A) as pressing the right lever during the 683 
tone). Judgement bias, or decision making about an ambiguous cue, which is known to be 684 
influenced by affective state, can be probed by presenting an ambiguous tone that has a 685 
mipdoint frequency between the two reference cues (5kHz), and recording which lever the 686 
rat presses. If the rat is expecting the more positive outcome (indicative of an optimistic 687 
judgement bias), then they will more often choose the large reward lever, but if the rat is in a 688 
more negative affective state, they will expect the less positive outcome and more often 689 
choose the low reward lever, a pessimistic judgement bias. During the task, tones are 690 
presented within discrete trials, the format of which is depicted as a flow chart in (B). The 691 
task is self-initiated, and so each trial begins only once the rat makes a nosepoke entry into 692 
the magazine port. This is followed by a 5 second inter-trial interval (ITI), during which time 693 
the rat has to wait and refrain from making a lever press response. If the rat does press a 694 
lever, they are punished with a 10 second timeout (TO). The tone cue is presented for a 695 
maximum of 20 seconds following the ITI, or until the rat makes a lever press response. The 696 
outcome following each lever press depends on which tone was played, and which lever was 697 
pressed. Correct lever presses to either reference tone (high or low tones) results in the 698 
corresponding reward being delivered to the magazine, whilst incorrect lever presses results 699 
in a 10 second TO. This TO also occurs if the rat fails to make any lever press during the 20 700 
second tone presentation (an omission). During TOs, lever presses and magazine entries 701 
are recorded but have no consequences, meaning the rat has to wait to be able to begin the 702 




the software as having the same response properties as the high reward tone. I.e., if the rat 704 
makes a high reward lever press during a midpoint tone presentation classified in this way, 705 
then they will receive a four pellet reward, but will experience the 10 second TO if they make 706 
a low reward lever press. Similarly, if the midpoint tone is “classified” as having the same 707 
response properties as the low reward tone, then a high reward lever press would result in a 708 
TO, whilst a low reward lever press would result in delivery of the small reward. In this way, 709 
each lever is only every associated with the same reward outcome (i.e. four pellets for the 710 
high reward lever), but the midpoint tone becomes randomly reinforced, and so rats will 711 
maintain responding for this tone across multiple trials within a session, whilst being unable 712 
to learn a specific reward contingency to associate with the midpoint tone. 713 
 714 
Figure 2 – The effect of acute treatment with rapid acting antidepressant drugs and NMDA 715 
receptor antagonists on judgement bias of the midpoint ambiguous tone.  716 
Ketamine (0.0, 1.0 mg/kg; n = 13), scopolamine (0.0, 0.03, 0.1 mg/kg; n = 16), CP-101,606 717 
(Expt 1: 0.0, 0.3, 1.0, 3.0 mg/kg, n = 15; Expt 2: 0.0, 6.0 mg/kg, n = 15), lanicemine (0.0, 0.3, 718 
1.0, 3.0 mg/kg; n = 16), memantine (0.0, 0.1, 0.3, 1.0 mg/kg; n = 16) and MK-801 (0.0, 0.01, 719 
0.03 mg/kg; n = 16 were administered acutely by intraperitoneal injection prior to testing on 720 
the judgement bias task. (A) Replicating previous studies, ketamine (1.0 mg/kg) positively 721 
changed CBI. (B) Scopolamine (0.1 mg/kg) also caused a positive change from baseline in 722 
CBI. (C) In experiment 1, there was no overall effect of CP-101,606 on change in CBI. A 723 
positive change was seen in experiment 2 with a higher 6.0 mg/kg dose. (D-G) Lanicemine, 724 
memantine, MK-801 and low doses of PCP did not induce a change in CBI for the midpoint 725 
tone at the doses tested. Data shown and represent mean ± SEM (bars and error bars) 726 
overlaid with individual data points for each rat. Dashed line (panel C) indicates separate, 727 
counterbalanced experiments. *p < 0.05; #p < 0.05 for a one-sample t-test for 3.0 mg/kg CP-728 




only from baseline). CP-101,606, ketamine, lanicemine, memantine, PCP: 60 min pre-730 
treatment; scopolamine, MK-801: 30 min pre-treatment 731 
 732 
Figure 3 – Behavioural data from the judgement bias task following acute treatment with 733 
high doses of ketamine.  734 
Acute doses of ketamine (Expt 1: 0.0, 10.0 mg/kg, n = 16; Expt 2: 0.0, 25.0 mg/kg, n = 16) 735 
were administered by intraperitoneal injection to measure their effect on judgement bias. (A) 736 
Neither high dose of ketamine caused a change in interpretation of the midpoint tone. (B) 737 
Both doses of ketamine increased accuracy for the low tone. (C) Both doses of ketamine 738 
increased response latencies across all three tones. (D) Omissions were increased across 739 
all three tones following both ketamine doses. (E) High doses of ketamine (10.0, 25.0 mg/kg) 740 
decreased premature responding. ***p < 0.001, **p < 0.01, *p < 0.05. Data represent mean ± 741 
SEM (panels B-E) with individual data points overlaid for each rat (panel A). Dashed lines 742 
indicate separate, counterbalanced experiments. 60 min pre-treatment. HT - high reward 743 
tone; MT - midpoint tone; LT - low reward tone. 744 
 745 
Figure 4 – Data from mPFC cannulated rats on the judgement bias task. 746 
Probe tests with no experimental manipulation were conducted before and after mPFC 747 
cannulation surgery to ensure that the surgery itself did not effect performance in the 748 
judgement bias task. (A) Cognitive bias index became more negative in the probe tests 749 
conducted after surgery. (B) The location of the injector placement was confirmed post-750 
mortem and black dots represent the location of the cannula tip as assessed from Cresyl 751 
violet-stained brain sections. Coronal sections are +3.7 mm to +2.5mm relative to bregma 752 
(Paxinos and Watson, 1998). (C-G) In the first infusion experiment, ketamine (Ket; 1.0 μg/μl) 753 
muscimol (Mus; 0.1 μg/μl), scopolamine (Sco; 0.1 μg/μl) or vehicle (Veh; 0.0 μg/μl; n = 13), 754 




judgement bias. (C) Ketamine, muscimol and scopolamine all caused a positive change in 756 
cognitive bias index (CBI) for the midpoint tone. (D) Muscimol decreased accuracy for both 757 
reference tones. (E) Muscimol increased response latencies for the high and midpoint tones. 758 
(F) For the high and low tones, muscimol increased omissions. (G) Muscimol also increased 759 
premature responding. Data represent mean ± SEM (panels A, C-G) with individual data 760 
points overlaid for each rat (panel A,C). Black dashed line (panel f) represents 50% accuracy 761 
depicting performance at chance. 5 min pre-treatment. ***p < 0.001, *p < 0.05. HT - high 762 
reward tone; MT - midpoint tone; LT - low reward tone. 763 
 764 
Figure 5 – Behavioural data from the judgement bias task following mPFC infusions of CP-765 
101,606.  766 
CP-101,606 (Expt 1: 00.0, 1.0 μg/μl, n = 13; Expt 2: 0.0, 3.0 μg/μl, n = 12) was administered 767 
by intracerebral infusion in the mPFC to measure the effect on judgement bias. (A) The 768 
higher dose of CP-101,606 (3.0 μg/μl) caused a positive change from baseline in CBI. (B) 769 
Accuracy was not altered by either dose of CP-101,606. (C) In experiment 1, CP-101,606 770 
(1.0 μg/μl) increased response latency for the midpoint tone. (D/E) There was no effect of 771 
either dose on omissions or premature responding, *p < 0.05. Data represent mean ± SEM 772 
(panels B-E) with individual data points overlaid for each rat (panel A). Dashed lines indicate 773 
separate, counterbalanced experiments. 5 min pre-treatment. HT - high reward tone; MT - 774 
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For all training stages, trial structure was as depicted in Figure S1 (except for magazine 
training which excludes any form of lever press response). Training stages 1-4 were 
conducted once per day, Monday to Friday, and consisted of a maximum of 100 trials, or 
lasted for 60 minutes. Where both tones were played (stages 3-4) tone type was equally spilt 
across the session (50 trials per tone). Baseline sessions also consisted of 100 trials, and 
were conducted Monday to Friday during baseline weeks between drug studies, and on 
Monday and Thursday during drug studies. Probe sessions consisted of 120 trials: 40 of 
each reference tone (2 and 8 kHz) and 40 midpoint tones (5 kHz). Pseudorandom tone 
presentation was achieved by splitting each training/baseline (probe) session into blocks of 
10 (12) trials, within which there were 5 (4) presentations of each tone frequency. Within a 
block, there could only be a maximum of n-1 consecutive tone presentations (i.e. in baseline 
sessions, a maximum of 4 consecutive trials of either 2 or 8 kHz). Omitted trials (no lever 
press during tone presentation; possible in stages 2-4) were punished with a 10 second 
timeout where the house light was turned on, and the animal was unable to initiate another 
trial. Incorrect trials (wrong lever for the tone presented; possible in stages 3-4) were also 
punished with a 10 second timeout with the house light on. Premature trials (lever press 
during the ITI; possible during stage 2-4) were similarly punished with a 10 second timeout 
with the house light on. Each new trial had to be self-initiated by the animal by making an 
entry into the magazine (this was signalled by the magazine light being turned on, and was 
switched off once animals made the magazine nose poke). Baseline session were the same 
format as reward magnitude training sessions, with animals required to repeat incorrect or 
omitted trials. Midpoint tones during the probe session were reinforced as follows: to 
program random reinforcement within the constraints of the software, the ambiguous 
midpoint tone was made up of two copies of the 5 kHz tone (75 dB), each of which was 
programmed to be classed as “correct” for one of the two lever press responses. This meant 
that the outcome associated with each of the two ambiguous tones could be programmed to 
be the same as one of the reference tones, hence resulting in random reinforcement. I.e., 
50% of the time lever presses for the midpoint tone had outcomes that were the same as the 
high reward tone (4 pellets or a timeout), whilst 50% of the time lever presses had outcomes 
that were the same as the low reward tone (timeout or 1 pellet). Responses to either of the 
“two” midpoint tones were analysed together. 
  
Table S2 - Summary of treatments used in the different cohorts. 
$Initial total n number for this manipulation is 15 as one rat had to be euthanised after the 
first infusion habituation session as dummy cannula could not be removed from the guide.  
  
Cohort # rats Acute drug treatment Doses (mg/kg) 
1 16 Memantine 
MK-801 
Lanicemine 
CP-101,606 (Experiment 1) 
CP-101,606 (Experiment 2) 
Scopolamine 
 
0.0, 0.1, 0.3, 1.0 
0.0, 0.01, 0.03 
0.0, 0.3, 1.0, 3.0 
0.0, 0.3, 1.0, 3.0 
0.0, 6.0 
0.0, 0.03, 0.1, 0.3 
 
2 16 Low dose PCP 
High dose ketamine (Experiment 1) 
High dose ketamine (Experiment 2) 
 




3 15$ Ketamine (systemic) 
mPFC infusions (Experiment 1): ketamine, 
muscimol, scopolamine 
0.0, 1.0 
0.0, 1.0, 0.1, 0.1 
μg/μl 
  mPFC infusion: CP-101,606 (Experiment 1) 
mPFC infusion: CP-101,606 (Experiment 2) 
 
0.0, 1.0 μg/μl 
0.0, 3.0 μg/μl 



















Behavioural data are presented as mean ± SEM. Drug studies are listed in chronological order for each cohort. Ketamine doses are listed in 
brackets.  
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brackets.  
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brackets.  







































Figure S1 – The effect of acute treatment with rapid acting antidepressant drugs and NMDA receptor antagonists on judgement 
bias of the midpoint ambiguous tone displayed as CBI.  
This figure shows data from Figure 1 displayed as cognitive bias index (CBI) scores. Ketamine (0.0, 1.0 mg/kg; n = 13), scopolamine (0.0, 0.03, 
0.1 mg/kg; n = 16), CP-101,606 (Expt 1: 0.0, 0.3, 1.0, 3.0 mg/kg, n = 15; Expt 2: 0.0, 6.0 mg/kg, n = 15), lanicemine (0.0, 0.3, 1.0, 3.0 mg/kg; n 
= 16), memantine (0.0, 0.1, 0.3, 1.0 mg/kg; n = 16) and MK-801 (0.0, 0.01, 0.03 mg/kg; n = 16 were administered acutely by intraperitoneal 
injection prior to testing on the judgement bias task. (A) Replicating previous studies, ketamine (1.0 mg/kg) caused CBI to shift in the positive 
direction. (B) Scopolamine (0.1 mg/kg) changed CBI scores to near zero, a positive shift. (C) CBI became moved in a positive direction after a 
6.0 mg/kg dose of CP-101,606. (D-G) Lanicemine, memantine, MK-801 and low doses of PCP did not alter CBI for the midpoint tone at the 
doses tested. Data shown and represent mean ± SEM (bars and error bars) overlaid with individual data points for each rat. Dashed line (panel 
C) indicates separate, counterbalanced experiments. *p < 0.05. CP-101,606, ketamine, lanicemine, memantine, PCP: 60 min pre-treatment; 
scopolamine, MK-801: 30 min pre-treatment. 
  
 
Figure S2 – The effect of acute treatment with high doses of ketamine, and mPFC infusions of rapid acting antidepressants on 
judgement bias of the midpoint ambiguous tone displayed as CBI.  
This figure shows data from Figures 2-4 displayed as cognitive bias index (CBI) scores. (A) From Figure 2: ketamine (Expt 1: 0.0, 10.0 mg/kg, n 
= 16; Expt 2: 0.0, 25.0 mg/kg, n = 16) were administered by intraperitoneal injection to measure their effect on judgement bias. Neither dose 
had any effect on CBI. (B) From Figure 3: ) In the first infusion experiment, ketamine (Ket; 1.0 μg/μl) muscimol (Mus; 0.1 μg/μl), scopolamine 
(Sco; 0.1 μg/μl) or vehicle (Veh; 0.0 μg/μl; n = 13), were administered by intracerebral infusion into the mPFC to measure the effect on 
judgement bias. All infuions caused positive changes in CBI. (C) From Figure 4: CP-101,606 (Expt 1: 00.0, 1.0 μg/μl, n = 13; Expt 2: 0.0, 3.0 
μg/μl, n = 12) was administered by intracerebral infusion in the mPFC to measure the effect on judgement bias. Only the higher dose (3.0 
mg/kg) caused CBI to become more positive. Data shown and represent mean ± SEM (bars and error bars) overlaid with individual data points 
for each rat. Dashed line (panel C) indicates separate, counterbalanced experiments. *p < 0.05. Ketamine (systemic): 60 min pre-treatment; 
infusions: 5 min pre-treatment. 
  




















Behavioural data are presented as mean ± SEM. Cells marked in bold indicate a significant difference for that measure, for that tone (compared 
to vehicle 0.0 mg/kg session for that drug) from a significant dose*tone interaction. Cells highlighted in grey indicate where a main effect of 
dose was found, indicating a difference for that drug treatment not specific to tone. * / light grey shading: p<0.05, ** / medium grey shading: 
p<0.01, *** / dark grey shading: p<0.001. 
 
  
Table S8 – Description of statistical analysis for other behavioural measures  
 
 
This table details the other behavioural measures (apart from cognitive bias index) that were 
analysed for each experimental manipulation and are presented in Table 1. ANOVA – 






Description Statistical analysis 
Response 
latency 
Each tone Time between presentation 
of the tone and response 
on the lever (correct lever 
for high and low reward 
tones, either lever for 
midpoint tone) 
Two-way repeated measures 






Number of correct 
responses made divided by 
the total number of 
responses made (correct + 
incorrect) for that tone 
Percentage 
omissions 
Each tone Number of trials where no 
lever press occurred during 
20 s tone presentation 
divided by total completed 






Number of trials where a 
response was made in the 
5 s inter-trial interval 
divided by total completed 
trials 
Repeated measures ANOVA with 
session as the within-subjects factor 
Figure S3 – CBI 
analysed by session 
split in half for 
systemic drugs that 
caused a positive 
change in bias. 
Ketamine (0.0, 1.0 
mg/kg; n = 13), 
scopolamine (0.0, 0.03, 
0.1 mg/kg; n = 16), CP-
101,606 (Expt 2: 0.0, 6.0 
mg/kg, n = 15) were 
administered acutely by 
intraperitoneal injection 
prior to testing on the 
judgement bias task. 
Data from these drug 
studies for doses that 
showed a positive 
change in judgement 
bias (ketamine: 1.0 
mg/kg; scopolamine: 0.1 
mg/kg) and CP-101,606: 
6.0 mg/kg) were re-
analysed by splitting 
each session in half, and 
comparing CBI for the 
first and last half of the 
sessions. Vehicle doses 
for each drug (panels 
A,C,E) are also shown 
for comparison. There is 
no consistent change 
between CBI scores 
across the first and 
second halves of a 
session for the drugs 
shown. Data shown are 
individual data points, 
linked for each individual 
rat.  
 
